Overview

Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with topotecan may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and topotecan in treating patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, Davis
Collaborator:
National Cancer Institute (NCI)
Treatments:
Bortezomib
Topotecan